PT  - JOURNAL ARTICLE
AU  - Uthara Vijai Kumar
AU  - Vijai Kumar Ratnavelu
AU  - Bharat Vaswani
TI  - Clinical profile of newly diagnosed patients of non small cell carcinima with epidermal growth factor receptor positivity on oral tyrosine kinase inhibitor therapy
DP  - 2013 Sep 01
TA  - European Respiratory Journal
PG  - P4495
VI  - 42
IP  - Suppl 57
4099  - http://erj.ersjournals.com/content/42/Suppl_57/P4495.short
4100  - http://erj.ersjournals.com/content/42/Suppl_57/P4495.full
SO  - Eur Respir J2013 Sep 01; 42
AB  - Lung cancer, of which Non-Small Cell Lung Cancer (NSCLC) is the most predominant form, can express activating mutations like Epidermal Growth Factor Receptor mutation that confer hypersensitivity to the tyrosine kinase inhibitors Geftinib and Erlotinib, oral chemotherapeutic agents, one of the many recent advances in management of NSCLC. Retrospective studies show that EGFR mutations were an independent predictor of response to treatment, progression free survival and overall survival in patients with NSCLC who were treated with Geftinib/ Erlotinib Objectives: To study the Clinical Profile of patients in a private hospital setting diagnosed with Non-Small Cell Carcinoma Lung with Epidermal Growth Factor Receptor (EGFR) mutation positivity. To assess Median Progression Free Survival (PFS), Objective Response Rate(ORR) and Overall Survival (OS) after Tyrosine Kinase Inhibitor therapy. Materials&Methods: design-Non Comparative Cohort study; No. 30; duration- January 1st 2010 to Feb 29th 2012. Patients visiting the Department of Pulmonary Medicine and diagnosed as Adenocarcinoma Lung with a positive mutation study were included in the study. Patient was started on oral tyrosine kinase inhibitor Tab. Gefitinib 250 mg once daily Follow up: Every 6 weeks; Results: Median age: 55 ; 76.67% of the study population were never smokers; the median PFS was 13.24 months; the objective response rate was 61.7% ; the median OS was 26.2 months Conclusions: EGFR mutation is more common in never smoker females who when treated with Tyrosine kinase inhibitor therapy show an increased PFS, OS and ORR when compared to previous studies.